$ci 2024 Q4 10-Q

Concept	2024 Q4	2024 Q3
Revenue		$63.69B
YoY Change		29.86%
Cost Of Revenue		$47.57B
YoY Change		41.4%
Gross Profit		$16.13B
YoY Change		4.67%
Gross Profit Margin		25.32%
Selling, General & Admin		$3.590B
YoY Change		-5.23%
% of Gross Profit		22.26%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$650.0M
YoY Change		-15.14%
% of Gross Profit		4.03%
Operating Expenses		$3.590B
YoY Change		-5.23%
Operating Profit		$2.576B
YoY Change		15.0%
Interest Expense		-$1.297B
YoY Change		242.22%
% of Operating Profit		-50.35%
Other Income/Expense, Net		-$376.0M
YoY Change		3.01%
Pretax Income		$1.192B
YoY Change		-35.22%
Income Tax		$367.0M
% Of Pretax Income		30.79%
Net Earnings		$825.0M
YoY Change		-43.06%
Net Earnings / Revenue		1.3%
Basic Earnings Per Share		$2.65
Diluted Earnings Per Share		$2.63
COMMON SHARES
Basic Shares Outstanding	278.2M shares	279.5M shares
Diluted Shares Outstanding		281.4M shares

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$6.752B
YoY Change		-29.25%
Cash & Equivalents		$5.888B
Short-Term Investments		$864.0M
Other Short-Term Assets		$2.667B
YoY Change		80.69%
Inventory		$5.083B
Prepaid Expenses
Receivables		$27.85B
Other Receivables		$0.00
Total Short-Term Assets		$49.22B
YoY Change		42.6%
LONG-TERM ASSETS
Property, Plant & Equipment		$3.594B
YoY Change		-8.41%
Goodwill		$44.37B
YoY Change		-3.13%
Intangibles		$29.79B
YoY Change		-4.89%
Long-Term Investments		$15.27B
YoY Change		-19.52%
Other Assets		$3.180B
YoY Change		1.05%
Total Long-Term Assets		$108.4B
YoY Change		-5.83%
TOTAL ASSETS
Total Short-Term Assets		$49.22B
Total Long-Term Assets		$108.4B
Total Assets		$157.6B
YoY Change		5.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$8.515B
YoY Change		10.97%
Accrued Expenses		$8.920B
YoY Change		-7.74%
Deferred Revenue
YoY Change
Short-Term Debt		$1.635B
YoY Change
Long-Term Debt Due		$937.0M
YoY Change		-69.24%
Total Short-Term Liabilities		$57.06B
YoY Change		21.25%
LONG-TERM LIABILITIES
Long-Term Debt		$30.23B
YoY Change		7.6%
Other Long-Term Liabilities		$3.033B
YoY Change		3.44%
Total Long-Term Liabilities		$3.033B
YoY Change		3.44%
TOTAL LIABILITIES
Total Short-Term Liabilities		$57.06B
Total Long-Term Liabilities		$3.033B
Total Liabilities		$115.3B
YoY Change		11.03%
SHAREHOLDERS EQUITY
Retained Earnings		$42.48B
YoY Change		3.66%
Common Stock		$31.19B
YoY Change		2.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$29.41B
YoY Change		23.9%
Treasury Stock Shares
Shareholders Equity		$42.10B
YoY Change
Total Liabilities & Shareholders Equity		$157.6B
YoY Change		5.34%

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		$825.0M
YoY Change		-43.06%
Depreciation, Depletion And Amortization		$650.0M
YoY Change		-15.14%
Cash From Operating Activities		$46.00M
YoY Change		-98.37%
INVESTING ACTIVITIES
Capital Expenditures		$399.0M
YoY Change		-0.99%
Acquisitions
YoY Change
Other Investing Activities		-$377.0M
YoY Change		-59.64%
Cash From Investing Activities		-$776.0M
YoY Change		-41.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		439.0M
YoY Change		-117.07%
NET CHANGE
Cash From Operating Activities		46.00M
Cash From Investing Activities		-776.0M
Cash From Financing Activities		439.0M
Net Change In Cash		-291.0M
YoY Change		-73.13%
FREE CASH FLOW
Cash From Operating Activities		$46.00M
Capital Expenditures		$399.0M
Free Cash Flow		-$353.0M
YoY Change		-114.57%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-4991898
	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 Cottage Grove Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bloomfield
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06002
	dei	City Area Code CityAreaCode	860
	dei	Local Phone Number LocalPhoneNumber	226-6000
	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01
	dei	Trading Symbol TradingSymbol	CI
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	278152606	shares
CY2024Q3	us-gaap	Premiums Earned Net PremiumsEarnedNet	11436000000	usd
CY2023Q3	us-gaap	Premiums Earned Net PremiumsEarnedNet	10998000000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	34493000000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	33062000000	usd
CY2024Q3	us-gaap	Net Investment Income NetInvestmentIncome	85000000	usd
CY2023Q3	us-gaap	Net Investment Income NetInvestmentIncome	321000000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	696000000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	876000000	usd
CY2024Q3	us-gaap	Revenues Revenues	63694000000	usd
CY2023Q3	us-gaap	Revenues Revenues	49048000000	usd
	us-gaap	Revenues Revenues	181472000000	usd
	us-gaap	Revenues Revenues	144151000000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	47565000000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	98540000000	usd
CY2024Q3	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	9527000000	usd
CY2023Q3	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	8927000000	usd
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	28482000000	usd
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	27007000000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3590000000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2576000000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2240000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	7244000000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	6476000000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	41000000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	232000000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1711000000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3674000000	usd
CY2024Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	27846000000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	17722000000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	5083000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	5645000000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2667000000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2169000000	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	33639000000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	133488000000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3788000000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10979000000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	436000000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	454000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1279000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1368000000	usd
CY2024Q3	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	61118000000	usd
CY2024Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-87000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-106000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-21000000	usd
CY2024Q3	ci	Realized Investment Gain Loss RealizedInvestmentGainLoss	-921000000	usd
CY2023Q3	ci	Realized Investment Gain Loss RealizedInvestmentGainLoss	-14000000	usd
	ci	Realized Investment Gain Loss RealizedInvestmentGainLoss	-2805000000	usd
	ci	Realized Investment Gain Loss RealizedInvestmentGainLoss	-44000000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1192000000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1840000000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	13.89
CY2024Q3	us-gaap	Profit Loss ProfitLoss	825000000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	1449000000	usd
	us-gaap	Profit Loss ProfitLoss	2242000000	usd
	us-gaap	Profit Loss ProfitLoss	4265000000	usd
CY2024Q3	ci	Other Comprehensive Income Loss Available For Sale Securities And Derivatives Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax	264000000	usd
CY2023Q3	ci	Other Comprehensive Income Loss Available For Sale Securities And Derivatives Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax	-192000000	usd
	ci	Other Comprehensive Income Loss Available For Sale Securities And Derivatives Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax	493000000	usd
	ci	Other Comprehensive Income Loss Available For Sale Securities And Derivatives Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax	22000000	usd
CY2024Q3	ci	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Including Temporary Equity OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity	39000000	usd
CY2023Q3	ci	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Including Temporary Equity OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity	-29000000	usd
	ci	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Including Temporary Equity OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity	8000000	usd
	ci	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Including Temporary Equity OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity	-32000000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-4000000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-8000000	usd
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-25000000	usd
CY2024Q3	ci	Other Comprehensive Income Loss Net Of Tax Including Temporary Equity OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity	279000000	usd
CY2023Q3	ci	Other Comprehensive Income Loss Net Of Tax Including Temporary Equity OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity	-241000000	usd
	ci	Other Comprehensive Income Loss Net Of Tax Including Temporary Equity OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity	-299000000	usd
	ci	Other Comprehensive Income Loss Net Of Tax Including Temporary Equity OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity	-461000000	usd
CY2024Q3	ci	Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Including Temporary Equity ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity	1104000000	usd
CY2023Q3	ci	Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Including Temporary Equity ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity	1208000000	usd
	ci	Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Including Temporary Equity ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity	1943000000	usd
	ci	Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Including Temporary Equity ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity	3804000000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	37000000	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	116000000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	4000000	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	232000000	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	14000000	usd
CY2024Q3	us-gaap	Assets Assets	157639000000	usd
CY2023Q4	us-gaap	Assets Assets	152761000000	usd
CY2024Q3	ci	Insurance And Contractholder Liabilities Current InsuranceAndContractholderLiabilitiesCurrent	5477000000	usd
CY2023Q4	ci	Insurance And Contractholder Liabilities Current InsuranceAndContractholderLiabilitiesCurrent	5514000000	usd
CY2024Q3	ci	Pharmacy And Service Costs Payable PharmacyAndServiceCostsPayable	28801000000	usd
CY2024Q3	us-gaap	Debt Current DebtCurrent	2572000000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	294058000	shares
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2939000	shares
CY2023Q4	us-gaap	Supplier Finance Program Obligation Current Statement Of Financial Position Extensible Enumeration SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2024#AccountsPayableCurrent
CY2023Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-21000000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	17722000000	usd
CY2024Q3	ci	Allowance For Receivables Current AllowanceForReceivablesCurrent	4600000000	usd
CY2023Q4	ci	Allowance For Receivables Current AllowanceForReceivablesCurrent	3700000000	usd
CY2024Q3	ci	Accounts Receivable Uncommitted Factoring Facility Accounts Receivable Received But Not Remitted AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted	1100000000	usd
CY2024Q3	us-gaap	Supplier Finance Program Obligation Current SupplierFinanceProgramObligationCurrent	1600000000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	739000000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	739000000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1408000000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1408000000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	278457000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	278457000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	294058000	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3073000	shares
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2939000	shares
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001739940
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10760000000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1073000000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1086000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1018000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1060000000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	825000000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	1449000000	usd
	us-gaap	Profit Loss ProfitLoss	2242000000	usd
	us-gaap	Profit Loss ProfitLoss	4265000000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	86000000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	41000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	232000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	130000000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	739000000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1408000000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2010000000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4135000000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.65
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.79
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.03
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.63
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.05
CY2024Q3	ci	Oci Liability For Future Policy Benefit And Market Risk Benefit Instrument Specific Credit Risk Gain Loss After Reclassification Adjustment And Tax Portion Attributable To Parent OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent	-28000000	usd
CY2023Q3	ci	Oci Liability For Future Policy Benefit And Market Risk Benefit Instrument Specific Credit Risk Gain Loss After Reclassification Adjustment And Tax Portion Attributable To Parent OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent	-28000000	usd
	ci	Oci Liability For Future Policy Benefit And Market Risk Benefit Instrument Specific Credit Risk Gain Loss After Reclassification Adjustment And Tax Portion Attributable To Parent OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent	-800000000	usd
	ci	Oci Liability For Future Policy Benefit And Market Risk Benefit Instrument Specific Credit Risk Gain Loss After Reclassification Adjustment And Tax Portion Attributable To Parent OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent	-476000000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	86000000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	86000000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1167000000	usd
CY2024Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	6874000000	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	3068000000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	49222000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	37351000000	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	15270000000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	17985000000	usd
CY2024Q3	ci	Reinsurance Recoverables Non Current ReinsuranceRecoverablesNonCurrent	4557000000	usd
CY2023Q4	ci	Reinsurance Recoverables Non Current ReinsuranceRecoverablesNonCurrent	4835000000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	3594000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	3695000000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	44374000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	44259000000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29791000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	30863000000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3180000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3421000000	usd
CY2024Q3	us-gaap	Separate Account Assets SeparateAccountAssets	7651000000	usd
CY2024Q3	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	2922000000	usd
CY2023Q4	ci	Pharmacy And Service Costs Payable PharmacyAndServiceCostsPayable	19815000000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	8515000000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8553000000	usd
CY2024Q3	ci	Accrued Expenses And Other Liabilities AccruedExpensesAndOtherLiabilities	8920000000	usd
CY2023Q4	ci	Accrued Expenses And Other Liabilities AccruedExpensesAndOtherLiabilities	9955000000	usd
CY2023Q4	us-gaap	Debt Current DebtCurrent	2775000000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	2104000000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	57060000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48716000000	usd
CY2024Q3	ci	Insurance And Contractholder Liabilities Noncurrent InsuranceAndContractholderLiabilitiesNoncurrent	10573000000	usd
CY2023Q4	ci	Insurance And Contractholder Liabilities Noncurrent InsuranceAndContractholderLiabilitiesNoncurrent	10904000000	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6794000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7173000000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3033000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3441000000	usd
CY2024Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	30230000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	28155000000	usd
CY2024Q3	us-gaap	Separate Accounts Liability SeparateAccountsLiability	7651000000	usd
CY2023Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	7430000000	usd
CY2024Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	591000000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	115341000000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	4000000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	31186000000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	30669000000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2163000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1864000000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	42480000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	41652000000	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	203000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	21000000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42298000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	46244000000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	157639000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152761000000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	402000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2024Q3	ci	Temporary Equity Other Comprehensive Income TemporaryEquityOtherComprehensiveIncome	0	usd
CY2024Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	825000000	usd
CY2024Q3	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	0	usd
CY2024Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.40
CY2024Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	391000000	usd
CY2024Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	usd
CY2024Q3	ci	Noncontrolling Interest Other Changes NoncontrollingInterestOtherChanges	-78000000	usd
CY2024Q3	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	0	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42298000000	usd
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	45464000000	usd
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	62000000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	122000000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-241000000	usd
CY2023Q3	ci	Temporary Equity Other Comprehensive Income TemporaryEquityOtherComprehensiveIncome	0	usd
CY2023Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	1412000000	usd
CY2023Q3	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	37000000	usd
CY2023Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.23
CY2023Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	362000000	usd
CY2023Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	681000000	usd
CY2023Q3	ci	Noncontrolling Interest Other Changes NoncontrollingInterestOtherChanges	-12000000	usd
CY2023Q3	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-35000000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	45702000000	usd
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	64000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	46244000000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	107000000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	400000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-299000000	usd
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	1182000000	usd
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	5057000000	usd
	ci	Noncontrolling Interest Other Changes NoncontrollingInterestOtherChanges	-50000000	usd
	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-107000000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42298000000	usd
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44688000000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	66000000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	222000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-461000000	usd
	ci	Temporary Equity Other Comprehensive Income TemporaryEquityOtherComprehensiveIncome	0	usd
	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	4149000000	usd
	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	116000000	usd
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	3.69
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	1093000000	usd
	ci	Noncontrolling Interest Other Changes NoncontrollingInterestOtherChanges	-18000000	usd
	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-118000000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	45702000000	usd
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	64000000	usd
	us-gaap	Profit Loss ProfitLoss	2242000000	usd
	us-gaap	Profit Loss ProfitLoss	4265000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2270000000	usd
	ci	Realized Investment Gain Loss RealizedInvestmentGainLoss	-44000000	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	351000000	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	303000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-106000000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-21000000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	10600000000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	1916000000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-577000000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-360000000	usd
	us-gaap	Increase Decrease In Reinsurance Recoverable IncreaseDecreaseInReinsuranceRecoverable	358000000	usd
	us-gaap	Increase Decrease In Reinsurance Recoverable IncreaseDecreaseInReinsuranceRecoverable	-281000000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-214000000	usd
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1482000000	usd
	ci	Increase Decrease In Pharmacy And Service Costs Payable IncreaseDecreaseInPharmacyAndServiceCostsPayable	8979000000	usd
	ci	Increase Decrease In Pharmacy And Service Costs Payable IncreaseDecreaseInPharmacyAndServiceCostsPayable	2250000000	usd
	ci	Increase Decrease In Accounts Payable Accrued And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities	-819000000	usd
	ci	Increase Decrease In Accounts Payable Accrued And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities	1337000000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-655000000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-255000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5151000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10346000000	usd
	ci	Proceeds From Sale Of Debt And Equity Securities ProceedsFromSaleOfDebtAndEquitySecurities	569000000	usd
	ci	Proceeds From Sale Of Debt And Equity Securities ProceedsFromSaleOfDebtAndEquitySecurities	757000000	usd
	ci	Proceeds From Maturities Prepayments And Calls Of Debt And Equity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities	585000000	usd
	ci	Proceeds From Maturities Prepayments And Calls Of Debt And Equity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities	715000000	usd
	us-gaap	Proceeds From Collection Of Loans Receivable ProceedsFromCollectionOfLoansReceivable	79000000	usd
	us-gaap	Proceeds From Collection Of Loans Receivable ProceedsFromCollectionOfLoansReceivable	86000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	567000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	453000000	usd
	ci	Payments To Acquire Debt And Equity Securities PaymentsToAcquireDebtAndEquitySecurities	943000000	usd
	ci	Payments To Acquire Debt And Equity Securities PaymentsToAcquireDebtAndEquitySecurities	4005000000	usd
	us-gaap	Payments To Acquire Mortgage Notes Receivable PaymentsToAcquireMortgageNotesReceivable	54000000	usd
	us-gaap	Payments To Acquire Mortgage Notes Receivable PaymentsToAcquireMortgageNotesReceivable	94000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5976000000	usd
CY2024Q3	ci	Transaction Related Costs After Tax TransactionRelatedCostsAfterTax	59000000	usd
	ci	Transaction Related Costs TransactionRelatedCosts	177000000	usd
	ci	Transaction Related Costs After Tax TransactionRelatedCostsAfterTax	135000000	usd
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2939000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3037000	shares
CY2024Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	401000000	usd
CY2024Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	1.40
CY2023Q4	ci	Accounts Receivable Uncommitted Factoring Facility Accounts Receivable Sold That Remain Outstanding AccountsReceivableUncommittedFactoringFacilityAccountsReceivableSoldThatRemainOutstanding	0	usd
CY2024Q3	us-gaap	Supplier Finance Program Obligation Current Statement Of Financial Position Extensible Enumeration SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2024#AccountsPayableCurrent
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax		usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax		usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax		usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax		usd
CY2024Q3	ci	Impairments Requiring Certain Assets And Liabiliaties To Be Measured At Fair Value ImpairmentsRequiringCertainAssetsAndLiabiliatiesToBeMeasuredAtFairValue		usd
	ci	Impairments Requiring Certain Assets And Liabiliaties To Be Measured At Fair Value ImpairmentsRequiringCertainAssetsAndLiabiliatiesToBeMeasuredAtFairValue		usd
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount		usd
CY2023Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount		usd
	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount		usd
	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount		usd
CY2024Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount		usd
CY2023Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount		usd
	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount		usd
	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount		usd
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38769
	dei	Entity Registrant Name EntityRegistrantName	The Cigna Group
CY2023Q3	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	46808000000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	174228000000	usd
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	137675000000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-376000000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-365000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3260000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5325000000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	367000000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	391000000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	130000000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1018000000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5888000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7822000000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	864000000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	925000000	usd
CY2023Q4	us-gaap	Separate Account Assets SeparateAccountAssets	7430000000	usd
CY2024Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	2775000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	106410000000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0	usd
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	107000000	usd
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	29412000000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	24238000000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	42095000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	46223000000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	400000000	shares
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41527000000	usd
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	136000000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	279000000	usd
	ci	Temporary Equity Other Comprehensive Income TemporaryEquityOtherComprehensiveIncome	0	usd
	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	2242000000	usd
	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	0	usd
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	4.20
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1785000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2129000000	usd
	ci	Realized Investment Gain Loss RealizedInvestmentGainLoss	-2805000000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	1028000000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	891000000	usd
	ci	Payments For Proceeds From Property Plant And Equipment PaymentsForProceedsFromPropertyPlantAndEquipment	1069000000	usd
	ci	Payments For Proceeds From Property Plant And Equipment PaymentsForProceedsFromPropertyPlantAndEquipment	1208000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	132000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	443000000	usd
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	usd
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	13000000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	485000000	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	117000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1911000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4734000000	usd
	us-gaap	Additions To Contract Holders Funds AdditionsToContractHoldersFunds	120000000	usd
	us-gaap	Additions To Contract Holders Funds AdditionsToContractHoldersFunds	127000000	usd
	us-gaap	Withdrawal From Contract Holders Funds WithdrawalFromContractHoldersFunds	180000000	usd
	us-gaap	Withdrawal From Contract Holders Funds WithdrawalFromContractHoldersFunds	139000000	usd
	ci	Proceeds From Repayments Of Other Short Term Debt ProceedsFromRepaymentsOfOtherShortTermDebt	366000000	usd
	ci	Proceeds From Repayments Of Other Short Term Debt ProceedsFromRepaymentsOfOtherShortTermDebt	1484000000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3000000000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2967000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	4462000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1491000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	5012000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1740000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	283000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	113000000	usd
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	1183000000	usd
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	1092000000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-255000000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-321000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4399000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3044000000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6000000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1153000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2570000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8337000000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7184000000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8546000000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	1249000000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	0	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5935000000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8546000000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	839000000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1380000000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1037000000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1019000000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<div style="margin-bottom:10pt"><span id="i0eaf2456d5f04af69c938065bbe0ced8_4268"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 – Description of Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. Powered by our people and our brands, we advance our mission to improve the health and vitality of those we serve. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental and related products and services. The majority of these products and services are offered through employers and other entities such as governmental and non-governmental organizations, unions and associations. Cigna Healthcare also offers health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A full description of our segments follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Evernorth Health Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which partner with health plans, employers, governmental organizations and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through Care Delivery and Management Solutions. The Company's reporting units remain aligned with its operating segments and Evernorth Health Services' goodwill was allocated on a relative fair value basis during the three months ended March 31, 2024.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cigna Healthcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and specialty benefits and solutions for insured and self-insured clients, Medicare Advantage, Medicare Supplement and Medicare Stand-Alone Prescription Drug Plans for seniors and individual health insurance plans. International Health provides health care solutions in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the <span style="-sec-ix-hidden:f-510">U.S. Healthcare</span> operating segment to Health Care Service Corporation ("HCSC") for approximately $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions, including adjustments to align with the final balance sheet of the divested businesses (the "HCSC transaction"). See Note 5 to the Consolidated Financial Statements for further information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> comprises the remainder of our business operations, which includes our continuing business (corporate-owned life insurance ("COLI")) and our run-off and other non-strategic businesses. Our run-off businesses include (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013, (ii) settlement annuity business, and (iii) individual life insurance and annuity and retirement benefits businesses which were sold through reinsurance agreements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs and eliminations for products and services sold between segments.</span></div>
CY2024Q3	ci	Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale	13708000000	usd
CY2023Q4	ci	Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale	8169000000	usd
CY2024Q3	ci	Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale	12615000000	usd
CY2023Q4	ci	Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale	8044000000	usd
CY2024Q3	ci	Insurance Customer Receivables Before Reclassification To Disposal Group Assets Held For Sale InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale	2732000000	usd
CY2023Q4	ci	Insurance Customer Receivables Before Reclassification To Disposal Group Assets Held For Sale InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale	2359000000	usd
CY2024Q3	ci	Accounts And Other Receivables Net Current Before Reclassification To Disposal Group Assets Held For Sale AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale	323000000	usd
CY2023Q4	ci	Accounts And Other Receivables Net Current Before Reclassification To Disposal Group Assets Held For Sale AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale	272000000	usd
CY2024Q3	ci	Receivables Net Current Before Reclassification To Disposal Group Assets Held For Sale ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale	29378000000	usd
CY2023Q4	ci	Receivables Net Current Before Reclassification To Disposal Group Assets Held For Sale ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale	18844000000	usd
CY2024Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	27846000000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	88000000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	90000000	usd
CY2023Q3	ci	Accounts Receivable Uncommitted Factoring Facility Initial Term AccountsReceivableUncommittedFactoringFacilityInitialTerm	P2Y
CY2023Q3	ci	Accounts Receivable Uncommitted Factoring Facility Automatic Renewal Term AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm	P1Y
CY2023Q3	ci	Accounts Receivable Uncommitted Factoring Facility Total Capacity AccountsReceivableUncommittedFactoringFacilityTotalCapacity	1000000000.0	usd
CY2024Q3	ci	Accounts Receivable Uncommitted Factoring Facility Total Capacity AccountsReceivableUncommittedFactoringFacilityTotalCapacity	1500000000	usd
CY2024Q3	ci	Accounts Receivable Uncommitted Factoring Facility Amount Sold AccountsReceivableUncommittedFactoringFacilityAmountSold	1300000000	usd
CY2023Q3	ci	Accounts Receivable Uncommitted Factoring Facility Amount Sold AccountsReceivableUncommittedFactoringFacilityAmountSold	1000000000.0	usd
	ci	Accounts Receivable Uncommitted Factoring Facility Amount Sold AccountsReceivableUncommittedFactoringFacilityAmountSold	4500000000	usd
	ci	Accounts Receivable Uncommitted Factoring Facility Amount Sold AccountsReceivableUncommittedFactoringFacilityAmountSold	1000000000.0	usd
CY2024Q3	ci	Accounts Receivable Uncommitted Factoring Facility Accounts Receivable Sold That Remain Outstanding AccountsReceivableUncommittedFactoringFacilityAccountsReceivableSoldThatRemainOutstanding	258000000	usd
CY2023Q4	ci	Accounts Receivable Uncommitted Factoring Facility Accounts Receivable Received But Not Remitted AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted	515000000	usd
CY2023Q4	us-gaap	Supplier Finance Program Obligation Current SupplierFinanceProgramObligationCurrent	1500000000	usd
CY2024Q3	ci	Supplier Finance Program Outstanding Payment Obligation Current Voluntarily Elected To Be Sold SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold	534000000	usd
CY2024Q3	ci	Transaction Related Costs TransactionRelatedCosts	77000000	usd
CY2023Q3	ci	Transaction Related Costs TransactionRelatedCosts	13000000	usd
CY2023Q3	ci	Transaction Related Costs After Tax TransactionRelatedCostsAfterTax	9000000	usd
	ci	Transaction Related Costs TransactionRelatedCosts	20000000	usd
	ci	Transaction Related Costs After Tax TransactionRelatedCostsAfterTax	15000000	usd
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3073000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	278457000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	281396000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	294058000	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3073000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	297131000	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.65
CY2024Q3	ci	Earnings Per Share Effect Of Dilution EarningsPerShareEffectOfDilution	-0.02
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.63
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.79
CY2023Q3	ci	Earnings Per Share Effect Of Dilution EarningsPerShareEffectOfDilution	-0.05
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.74
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2010000000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2010000000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4135000000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4135000000	usd
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	282005000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	282005000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	294752000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	294752000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3037000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2911000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2911000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	282005000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3037000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	285042000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	294752000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2911000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	297663000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.13
	ci	Earnings Per Share Effect Of Dilution EarningsPerShareEffectOfDilution	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.03
	ci	Earnings Per Share Effect Of Dilution EarningsPerShareEffectOfDilution	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	13.89
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	122500000	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	107400000	shares
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	105700000	shares
CY2024Q3	us-gaap	Commercial Paper CommercialPaper	1635000000	usd
CY2023Q4	us-gaap	Commercial Paper CommercialPaper	1237000000	usd
CY2024Q3	ci	Other Short Term Debt Current Maturities Of Long Term Debt And Lease Obligations Current OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent	44000000	usd
CY2023Q4	ci	Other Short Term Debt Current Maturities Of Long Term Debt And Lease Obligations Current OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent	42000000	usd
CY2024Q3	us-gaap	Debt Current DebtCurrent	2572000000	usd
CY2023Q4	us-gaap	Debt Current DebtCurrent	2775000000	usd
CY2024Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	50000000	usd
CY2023Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	66000000	usd
CY2024Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	30230000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	28155000000	usd

dei

Amendment Flag

AmendmentFlag

false

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2024

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

DE

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

82-4991898

dei

Entity Address Address Line1

EntityAddressAddressLine1

900 Cottage Grove Road

dei

Entity Address City Or Town

EntityAddressCityOrTown

Bloomfield

dei

Entity Address State Or Province

EntityAddressStateOrProvince

CT

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

06002

dei

City Area Code

CityAreaCode

860

dei

Local Phone Number

LocalPhoneNumber

226-6000

dei

Security12b Title

Security12bTitle

Common Stock, Par Value $0.01

dei

Trading Symbol

TradingSymbol

CI

dei

Security Exchange Name

SecurityExchangeName

NYSE

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

dei

Entity Small Business

EntitySmallBusiness

false

dei

Entity Shell Company

EntityShellCompany

false

CY2024Q4

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

278152606

shares

CY2024Q3

us-gaap

Premiums Earned Net

PremiumsEarnedNet

11436000000

usd

CY2023Q3

us-gaap

Premiums Earned Net

PremiumsEarnedNet

10998000000

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

34493000000

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

33062000000

usd

CY2024Q3

us-gaap

Net Investment Income

NetInvestmentIncome

85000000

usd

CY2023Q3

us-gaap

Net Investment Income

NetInvestmentIncome

321000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

696000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

876000000

usd

CY2024Q3

us-gaap

Revenues

63694000000

usd

CY2023Q3

us-gaap

Revenues

49048000000

usd

us-gaap

Revenues

181472000000

usd

us-gaap

Revenues

144151000000

usd

CY2024Q3

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

47565000000

usd

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

98540000000

usd

CY2024Q3

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

9527000000

usd

CY2023Q3

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

8927000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

28482000000

usd

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

27007000000

usd

CY2024Q3

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

3590000000

usd

CY2024Q3

us-gaap

Operating Income Loss

OperatingIncomeLoss

2576000000

usd

CY2023Q3

us-gaap

Operating Income Loss

OperatingIncomeLoss

2240000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

7244000000

usd

us-gaap

Operating Income Loss

OperatingIncomeLoss

6476000000

usd

CY2023Q3

us-gaap

Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest

ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

41000000

usd

us-gaap

Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest

ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

232000000

usd

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

1711000000

usd

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

3674000000

usd

CY2024Q3

us-gaap

Receivables Net Current

ReceivablesNetCurrent

27846000000

usd

CY2023Q4

us-gaap

Receivables Net Current

ReceivablesNetCurrent

17722000000

usd

CY2024Q3

us-gaap

Inventory Net

InventoryNet

5083000000

usd

CY2023Q4

us-gaap

Inventory Net

InventoryNet

5645000000

usd

CY2024Q3

us-gaap

Other Assets Current

OtherAssetsCurrent

2667000000

usd

CY2023Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

2169000000

usd

dei

Document Type

DocumentType

10-Q

dei

Document Quarterly Report

DocumentQuarterlyReport

true

CY2023Q3

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

33639000000

usd

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

133488000000

usd

CY2023Q3

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

3788000000

usd

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

10979000000

usd

CY2024Q3

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

436000000

usd

CY2023Q3

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

454000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

1279000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

1368000000

usd

CY2024Q3

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

61118000000

usd

CY2024Q3

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

-87000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

-106000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

-21000000

usd

CY2024Q3

ci

Realized Investment Gain Loss

RealizedInvestmentGainLoss

-921000000

usd

CY2023Q3

ci

Realized Investment Gain Loss

RealizedInvestmentGainLoss

-14000000

usd

ci

Realized Investment Gain Loss

RealizedInvestmentGainLoss

-2805000000

usd

ci

Realized Investment Gain Loss

RealizedInvestmentGainLoss

-44000000

usd

CY2024Q3

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1192000000

usd

CY2023Q3

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1840000000

usd

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

13.89

CY2024Q3

us-gaap

Profit Loss

ProfitLoss

825000000

usd

CY2023Q3

us-gaap

Profit Loss

ProfitLoss

1449000000

usd

us-gaap

Profit Loss

ProfitLoss

2242000000

usd

us-gaap

Profit Loss

ProfitLoss

4265000000

usd

CY2024Q3

ci

Other Comprehensive Income Loss Available For Sale Securities And Derivatives Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax

264000000

usd

CY2023Q3

ci

Other Comprehensive Income Loss Available For Sale Securities And Derivatives Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax

-192000000

usd

ci

Other Comprehensive Income Loss Available For Sale Securities And Derivatives Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax

493000000

usd

ci

Other Comprehensive Income Loss Available For Sale Securities And Derivatives Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax

22000000

usd

CY2024Q3

ci

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Including Temporary Equity

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity

39000000

usd

CY2023Q3

ci

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Including Temporary Equity

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity

-29000000

usd

ci

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Including Temporary Equity

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity

8000000

usd

ci

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Including Temporary Equity

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity

-32000000

usd

CY2024Q3

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-4000000

usd

CY2023Q3

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-8000000

usd

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

0

usd

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-25000000

usd

CY2024Q3

ci

Other Comprehensive Income Loss Net Of Tax Including Temporary Equity

OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity

279000000

usd

CY2023Q3

ci

Other Comprehensive Income Loss Net Of Tax Including Temporary Equity

OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity

-241000000

usd

ci

Other Comprehensive Income Loss Net Of Tax Including Temporary Equity

OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity

-299000000

usd

ci

Other Comprehensive Income Loss Net Of Tax Including Temporary Equity

OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity

-461000000

usd

CY2024Q3

ci

Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Including Temporary Equity

ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity

1104000000

usd

CY2023Q3

ci

Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Including Temporary Equity

ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity

1208000000

usd

ci

Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Including Temporary Equity

ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity

1943000000

usd

ci

Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest Including Temporary Equity

ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity

3804000000

usd

CY2024Q3

us-gaap

Net Income Loss Attributable To Redeemable Noncontrolling Interest

NetIncomeLossAttributableToRedeemableNoncontrollingInterest

0

usd

CY2023Q3

us-gaap

Net Income Loss Attributable To Redeemable Noncontrolling Interest

NetIncomeLossAttributableToRedeemableNoncontrollingInterest

37000000

usd

us-gaap

Net Income Loss Attributable To Redeemable Noncontrolling Interest

NetIncomeLossAttributableToRedeemableNoncontrollingInterest

0

usd

us-gaap

Net Income Loss Attributable To Redeemable Noncontrolling Interest

NetIncomeLossAttributableToRedeemableNoncontrollingInterest

116000000

usd

CY2023Q3

us-gaap

Net Income Loss Attributable To Nonredeemable Noncontrolling Interest

NetIncomeLossAttributableToNonredeemableNoncontrollingInterest

4000000

usd

us-gaap

Net Income Loss Attributable To Nonredeemable Noncontrolling Interest

NetIncomeLossAttributableToNonredeemableNoncontrollingInterest

232000000

usd

us-gaap

Net Income Loss Attributable To Nonredeemable Noncontrolling Interest

NetIncomeLossAttributableToNonredeemableNoncontrollingInterest

14000000

usd

CY2024Q3

us-gaap

Assets

157639000000

usd

CY2023Q4

us-gaap

Assets

152761000000

usd

CY2024Q3

ci

Insurance And Contractholder Liabilities Current

InsuranceAndContractholderLiabilitiesCurrent

5477000000

usd

CY2023Q4

ci

Insurance And Contractholder Liabilities Current

InsuranceAndContractholderLiabilitiesCurrent

5514000000

usd

CY2024Q3

ci

Pharmacy And Service Costs Payable

PharmacyAndServiceCostsPayable

28801000000

usd

CY2024Q3

us-gaap

Debt Current

DebtCurrent

2572000000

usd

CY2023Q3

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

294058000

shares

CY2024Q3

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

2939000

shares

CY2023Q4

us-gaap

Supplier Finance Program Obligation Current Statement Of Financial Position Extensible Enumeration

SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration

http://fasb.org/us-gaap/2024#AccountsPayableCurrent

CY2023Q3

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

-21000000

usd

CY2023Q4

us-gaap

Receivables Net Current

ReceivablesNetCurrent

17722000000

usd

CY2024Q3

ci

Allowance For Receivables Current

AllowanceForReceivablesCurrent

4600000000

usd

CY2023Q4

ci

Allowance For Receivables Current

AllowanceForReceivablesCurrent

3700000000

usd

CY2024Q3

ci

Accounts Receivable Uncommitted Factoring Facility Accounts Receivable Received But Not Remitted

AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted

1100000000

usd

CY2024Q3

us-gaap

Supplier Finance Program Obligation Current

SupplierFinanceProgramObligationCurrent

1600000000

usd

CY2024Q3

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

739000000

usd

CY2024Q3

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

739000000

usd

CY2023Q3

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

1408000000

usd

CY2023Q3

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

1408000000

usd

CY2024Q3

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

278457000

shares

CY2024Q3

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

278457000

shares

CY2023Q3

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

294058000

shares

CY2023Q3

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

3073000

shares

CY2024Q3

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

2939000

shares

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

Q3

dei

Entity Central Index Key

EntityCentralIndexKey

0001739940

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

10760000000

usd

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

-1073000000

usd

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

-1086000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1018000000

usd

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1060000000

usd

CY2024Q3

us-gaap

Profit Loss

ProfitLoss

825000000

usd

CY2023Q3

us-gaap

Profit Loss

ProfitLoss

1449000000

usd

us-gaap

Profit Loss

ProfitLoss

2242000000

usd

us-gaap

Profit Loss

ProfitLoss

4265000000

usd

CY2024Q3

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

86000000

usd

CY2023Q3

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

41000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

232000000

usd

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

130000000

usd

CY2024Q3

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

739000000

usd

CY2023Q3

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

1408000000

usd

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

2010000000

usd

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

4135000000

usd

CY2024Q3

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

2.65

CY2023Q3

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

4.79

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

7.13

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

14.03

CY2024Q3

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

2.63

CY2023Q3

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

4.74

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

7.05

CY2024Q3

ci

Oci Liability For Future Policy Benefit And Market Risk Benefit Instrument Specific Credit Risk Gain Loss After Reclassification Adjustment And Tax Portion Attributable To Parent

OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent

-28000000

usd

CY2023Q3

ci

Oci Liability For Future Policy Benefit And Market Risk Benefit Instrument Specific Credit Risk Gain Loss After Reclassification Adjustment And Tax Portion Attributable To Parent

OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent

-28000000

usd

ci

Oci Liability For Future Policy Benefit And Market Risk Benefit Instrument Specific Credit Risk Gain Loss After Reclassification Adjustment And Tax Portion Attributable To Parent

OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent

-800000000

usd

ci

Oci Liability For Future Policy Benefit And Market Risk Benefit Instrument Specific Credit Risk Gain Loss After Reclassification Adjustment And Tax Portion Attributable To Parent

OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent

-476000000

usd

CY2024Q3

us-gaap

Net Income Loss Attributable To Nonredeemable Noncontrolling Interest

NetIncomeLossAttributableToNonredeemableNoncontrollingInterest

86000000

usd

CY2024Q3

us-gaap

Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest

ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

86000000

usd

CY2023Q3

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

1167000000

usd

CY2024Q3

us-gaap

Assets Of Disposal Group Including Discontinued Operation Current

AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

6874000000

usd

CY2023Q4

us-gaap

Assets Of Disposal Group Including Discontinued Operation Current

AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

3068000000

usd

CY2024Q3

us-gaap

Assets Current

AssetsCurrent

49222000000

usd

CY2023Q4

us-gaap

Assets Current

AssetsCurrent

37351000000

usd

CY2024Q3

us-gaap

Long Term Investments

LongTermInvestments

15270000000

usd

CY2023Q4

us-gaap

Long Term Investments

LongTermInvestments

17985000000

usd

CY2024Q3

ci

Reinsurance Recoverables Non Current

ReinsuranceRecoverablesNonCurrent

4557000000

usd

CY2023Q4

ci

Reinsurance Recoverables Non Current

ReinsuranceRecoverablesNonCurrent

4835000000

usd

CY2024Q3

us-gaap

Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization

PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization

3594000000

usd

CY2023Q4

us-gaap

Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization

PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization

3695000000

usd

CY2024Q3

us-gaap

Goodwill

44374000000

usd

CY2023Q4

us-gaap

Goodwill

44259000000

usd

CY2024Q3

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

29791000000

usd

CY2023Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

30863000000

usd

CY2024Q3

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

3180000000

usd

CY2023Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

3421000000

usd

CY2024Q3

us-gaap

Separate Account Assets

SeparateAccountAssets

7651000000

usd

CY2024Q3

us-gaap

Disposal Group Including Discontinued Operation Assets Noncurrent

DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent

0

usd

CY2023Q4

us-gaap

Disposal Group Including Discontinued Operation Assets Noncurrent

DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent

2922000000

usd

CY2023Q4

ci

Pharmacy And Service Costs Payable

PharmacyAndServiceCostsPayable

19815000000

usd

CY2024Q3

us-gaap

Accounts Payable Current

AccountsPayableCurrent

8515000000

usd

CY2023Q4

us-gaap

Accounts Payable Current

AccountsPayableCurrent

8553000000

usd

CY2024Q3

ci

Accrued Expenses And Other Liabilities

AccruedExpensesAndOtherLiabilities

8920000000

usd

CY2023Q4

ci

Accrued Expenses And Other Liabilities

AccruedExpensesAndOtherLiabilities

9955000000

usd

CY2023Q4

us-gaap

Debt Current

DebtCurrent

2775000000

usd

CY2023Q4

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Current

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

2104000000

usd

CY2024Q3

us-gaap

Liabilities Current

LiabilitiesCurrent

57060000000

usd

CY2023Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

48716000000

usd

CY2024Q3

ci

Insurance And Contractholder Liabilities Noncurrent

InsuranceAndContractholderLiabilitiesNoncurrent

10573000000

usd

CY2023Q4

ci

Insurance And Contractholder Liabilities Noncurrent

InsuranceAndContractholderLiabilitiesNoncurrent

10904000000

usd

CY2024Q3

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

6794000000

usd

CY2023Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

7173000000

usd

CY2024Q3

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

3033000000

usd

CY2023Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

3441000000

usd

CY2024Q3

us-gaap

Long Term Debt And Capital Lease Obligations

LongTermDebtAndCapitalLeaseObligations

30230000000

usd

CY2023Q4

us-gaap

Long Term Debt And Capital Lease Obligations

LongTermDebtAndCapitalLeaseObligations

28155000000

usd

CY2024Q3

us-gaap

Separate Accounts Liability

SeparateAccountsLiability

7651000000

usd

CY2023Q4

us-gaap

Separate Accounts Liability

SeparateAccountsLiability

7430000000

usd

CY2024Q3

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Noncurrent

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent

0

usd

CY2023Q4

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Noncurrent

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent

591000000

usd

CY2024Q3

us-gaap

Liabilities

115341000000

usd

CY2024Q3

us-gaap

Common Stock Value

CommonStockValue

4000000

usd

CY2023Q4

us-gaap

Common Stock Value

CommonStockValue

4000000

usd

CY2024Q3

us-gaap

Additional Paid In Capital Common Stock

AdditionalPaidInCapitalCommonStock

31186000000

usd

CY2023Q4

us-gaap

Additional Paid In Capital Common Stock

AdditionalPaidInCapitalCommonStock

30669000000

usd

CY2024Q3

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-2163000000

usd

CY2023Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-1864000000

usd

CY2024Q3

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

42480000000

usd

CY2023Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

41652000000

usd

CY2024Q3

us-gaap

Minority Interest

MinorityInterest

203000000

usd

CY2023Q4

us-gaap

Minority Interest

MinorityInterest

21000000

usd

CY2024Q3

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

42298000000

usd

CY2023Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

46244000000

usd

CY2024Q3

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

157639000000

usd

CY2023Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

152761000000

usd

CY2024Q3

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2023Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2024Q3

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

402000000

shares

CY2023Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

600000000

shares

CY2024Q3

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

600000000

shares

CY2024Q3

ci

Temporary Equity Other Comprehensive Income

TemporaryEquityOtherComprehensiveIncome

0

usd

CY2024Q3

us-gaap

Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest

NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest

825000000

usd

CY2024Q3

us-gaap

Temporary Equity Net Income

TemporaryEquityNetIncome

0

usd

CY2024Q3

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.40

CY2024Q3

us-gaap

Dividends Common Stock Cash

DividendsCommonStockCash

391000000

usd

CY2024Q3

us-gaap

Treasury Stock Value Acquired Cost Method

TreasuryStockValueAcquiredCostMethod

0

usd

CY2024Q3

ci

Noncontrolling Interest Other Changes

NoncontrollingInterestOtherChanges

-78000000

usd

CY2024Q3

us-gaap

Temporary Equity Other Changes

TemporaryEquityOtherChanges

0

usd

CY2024Q3

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

42298000000

usd

CY2024Q3

us-gaap

Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests

TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

0

usd

CY2023Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

45464000000

usd

CY2023Q2

us-gaap

Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests

TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

62000000

usd

CY2023Q3

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

122000000

usd

CY2023Q3

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-241000000

usd

CY2023Q3

ci

Temporary Equity Other Comprehensive Income

TemporaryEquityOtherComprehensiveIncome

0

usd

CY2023Q3

us-gaap

Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest

NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest

1412000000

usd

CY2023Q3

us-gaap

Temporary Equity Net Income

TemporaryEquityNetIncome

37000000

usd

CY2023Q3

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.23

CY2023Q3

us-gaap

Dividends Common Stock Cash

DividendsCommonStockCash

362000000

usd

CY2023Q3

us-gaap

Treasury Stock Value Acquired Cost Method

TreasuryStockValueAcquiredCostMethod

681000000

usd

CY2023Q3

ci

Noncontrolling Interest Other Changes

NoncontrollingInterestOtherChanges

-12000000

usd

CY2023Q3

us-gaap

Temporary Equity Other Changes

TemporaryEquityOtherChanges

-35000000

usd

CY2023Q3

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

45702000000

usd

CY2023Q3

us-gaap

Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests

TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

64000000

usd

CY2023Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

46244000000

usd

CY2023Q4

us-gaap

Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests

TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

107000000

usd

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

400000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-299000000

usd

us-gaap

Dividends Common Stock Cash

DividendsCommonStockCash

1182000000

usd

us-gaap

Treasury Stock Value Acquired Cost Method

TreasuryStockValueAcquiredCostMethod

5057000000

usd

ci

Noncontrolling Interest Other Changes

NoncontrollingInterestOtherChanges

-50000000

usd

us-gaap

Temporary Equity Other Changes

TemporaryEquityOtherChanges

-107000000

usd

CY2024Q3

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

42298000000

usd

CY2024Q3

us-gaap

Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests

TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

0

usd

CY2022Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

44688000000

usd

CY2022Q4

us-gaap

Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests

TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

66000000

usd

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

222000000

usd

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-461000000

usd

ci

Temporary Equity Other Comprehensive Income

TemporaryEquityOtherComprehensiveIncome

0

usd

us-gaap

Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest

NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest

4149000000

usd

us-gaap

Temporary Equity Net Income

TemporaryEquityNetIncome

116000000

usd

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

3.69

us-gaap

Dividends Common Stock Cash

DividendsCommonStockCash

1093000000

usd

ci

Noncontrolling Interest Other Changes

NoncontrollingInterestOtherChanges

-18000000

usd

us-gaap

Temporary Equity Other Changes

TemporaryEquityOtherChanges

-118000000

usd

CY2023Q3

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

45702000000

usd

CY2023Q3

us-gaap

Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests

TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

64000000

usd

us-gaap

Profit Loss

ProfitLoss

2242000000

usd

us-gaap

Profit Loss

ProfitLoss

4265000000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

2270000000

usd

ci

Realized Investment Gain Loss

RealizedInvestmentGainLoss

-44000000

usd

us-gaap

Increase Decrease In Deferred Income Taxes

IncreaseDecreaseInDeferredIncomeTaxes

351000000

usd

us-gaap

Increase Decrease In Deferred Income Taxes

IncreaseDecreaseInDeferredIncomeTaxes

303000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

-106000000

usd

us-gaap

Gain Loss On Sale Of Business

GainLossOnSaleOfBusiness

-21000000

usd

us-gaap

Increase Decrease In Accounts And Other Receivables

IncreaseDecreaseInAccountsAndOtherReceivables

10600000000

usd

us-gaap

Increase Decrease In Accounts And Other Receivables

IncreaseDecreaseInAccountsAndOtherReceivables

1916000000

usd

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

-577000000

usd

us-gaap

Increase Decrease In Inventories

IncreaseDecreaseInInventories

-360000000

usd

us-gaap

Increase Decrease In Reinsurance Recoverable

IncreaseDecreaseInReinsuranceRecoverable

358000000

usd

us-gaap

Increase Decrease In Reinsurance Recoverable

IncreaseDecreaseInReinsuranceRecoverable

-281000000

usd

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

-214000000

usd

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

1482000000

usd

ci

Increase Decrease In Pharmacy And Service Costs Payable

IncreaseDecreaseInPharmacyAndServiceCostsPayable

8979000000

usd

ci

Increase Decrease In Pharmacy And Service Costs Payable

IncreaseDecreaseInPharmacyAndServiceCostsPayable

2250000000

usd

ci

Increase Decrease In Accounts Payable Accrued And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities

-819000000

usd

ci

Increase Decrease In Accounts Payable Accrued And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities

1337000000

usd

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-655000000

usd

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-255000000

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

5151000000

usd

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

10346000000

usd

ci

Proceeds From Sale Of Debt And Equity Securities

ProceedsFromSaleOfDebtAndEquitySecurities

569000000

usd

ci

Proceeds From Sale Of Debt And Equity Securities

ProceedsFromSaleOfDebtAndEquitySecurities

757000000

usd

ci

Proceeds From Maturities Prepayments And Calls Of Debt And Equity Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities

585000000

usd

ci

Proceeds From Maturities Prepayments And Calls Of Debt And Equity Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities

715000000

usd

us-gaap

Proceeds From Collection Of Loans Receivable

ProceedsFromCollectionOfLoansReceivable

79000000

usd

us-gaap

Proceeds From Collection Of Loans Receivable

ProceedsFromCollectionOfLoansReceivable

86000000

usd

us-gaap

Proceeds From Sale And Maturity Of Other Investments

ProceedsFromSaleAndMaturityOfOtherInvestments

567000000

usd

us-gaap

Proceeds From Sale And Maturity Of Other Investments

ProceedsFromSaleAndMaturityOfOtherInvestments

453000000

usd

ci

Payments To Acquire Debt And Equity Securities

PaymentsToAcquireDebtAndEquitySecurities

943000000

usd

ci

Payments To Acquire Debt And Equity Securities

PaymentsToAcquireDebtAndEquitySecurities

4005000000

usd

us-gaap

Payments To Acquire Mortgage Notes Receivable

PaymentsToAcquireMortgageNotesReceivable

54000000

usd

us-gaap

Payments To Acquire Mortgage Notes Receivable

PaymentsToAcquireMortgageNotesReceivable

94000000

usd

CY2022Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

5976000000

usd

CY2024Q3

ci

Transaction Related Costs After Tax

TransactionRelatedCostsAfterTax

59000000

usd

ci

Transaction Related Costs

TransactionRelatedCosts

177000000

usd

ci

Transaction Related Costs After Tax

TransactionRelatedCostsAfterTax

135000000

usd

CY2024Q3

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

2939000

shares

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

3037000

shares

CY2024Q1

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

401000000

usd

CY2024Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.40

CY2023Q4

ci

Accounts Receivable Uncommitted Factoring Facility Accounts Receivable Sold That Remain Outstanding

AccountsReceivableUncommittedFactoringFacilityAccountsReceivableSoldThatRemainOutstanding

0

usd

CY2024Q3

us-gaap

Supplier Finance Program Obligation Current Statement Of Financial Position Extensible Enumeration

SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration

http://fasb.org/us-gaap/2024#AccountsPayableCurrent

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

usd

us-gaap

Derivative Gain Loss On Derivative Net

DerivativeGainLossOnDerivativeNet

usd

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

usd

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax

usd

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax

usd

us-gaap

Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax

OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax

usd

CY2024Q3

ci

Impairments Requiring Certain Assets And Liabiliaties To Be Measured At Fair Value

ImpairmentsRequiringCertainAssetsAndLiabiliatiesToBeMeasuredAtFairValue

usd

ci

Impairments Requiring Certain Assets And Liabiliaties To Be Measured At Fair Value

ImpairmentsRequiringCertainAssetsAndLiabiliatiesToBeMeasuredAtFairValue

usd

CY2024Q3

us-gaap

Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount

EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount

usd

CY2023Q3

us-gaap

Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount

EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount

usd

us-gaap

Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount

EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount

usd

us-gaap

Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount

EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount

usd

CY2024Q3

us-gaap

Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount

EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount

usd

CY2023Q3

us-gaap

Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount

EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount

usd

us-gaap

Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount

EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount

usd

us-gaap

Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount

EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount

usd

dei

Document Period End Date

DocumentPeriodEndDate

2024-09-30

dei

Document Transition Report

DocumentTransitionReport

false

dei

Entity File Number

EntityFileNumber

001-38769

dei

Entity Registrant Name

EntityRegistrantName

The Cigna Group

CY2023Q3

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

46808000000

usd

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

174228000000

usd

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

137675000000

usd

CY2024Q3

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

-376000000

usd

CY2023Q3

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

-365000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

3260000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5325000000

usd

CY2024Q3

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

367000000

usd

CY2023Q3

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

391000000

usd

us-gaap

Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest

ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

130000000

usd

CY2024Q3

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

1018000000

usd

CY2024Q3

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

5888000000

usd

CY2023Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

7822000000

usd

CY2024Q3

us-gaap

Short Term Investments

ShortTermInvestments

864000000

usd

CY2023Q4

us-gaap

Short Term Investments

ShortTermInvestments

925000000

usd

CY2023Q4

us-gaap

Separate Account Assets

SeparateAccountAssets

7430000000

usd

CY2024Q3

us-gaap

Liabilities Of Disposal Group Including Discontinued Operation Current

LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

2775000000

usd

CY2023Q4

us-gaap

Liabilities

106410000000

usd

CY2024Q3

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

usd

CY2023Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

usd

CY2024Q3

us-gaap

Redeemable Noncontrolling Interest Equity Carrying Amount

RedeemableNoncontrollingInterestEquityCarryingAmount

0

usd

CY2023Q4

us-gaap

Redeemable Noncontrolling Interest Equity Carrying Amount

RedeemableNoncontrollingInterestEquityCarryingAmount

107000000

usd

CY2024Q3

us-gaap

Treasury Stock Value

TreasuryStockValue

29412000000

usd

CY2023Q4

us-gaap

Treasury Stock Value

TreasuryStockValue

24238000000

usd

CY2024Q3

us-gaap

Stockholders Equity

StockholdersEquity

42095000000

usd

CY2023Q4

us-gaap

Stockholders Equity

StockholdersEquity

46223000000

usd

CY2023Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

400000000

shares

CY2024Q2

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

41527000000

usd

CY2024Q2

us-gaap

Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests

TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

0

usd

CY2024Q3

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

136000000

usd

CY2024Q3

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

279000000

usd

ci

Temporary Equity Other Comprehensive Income

TemporaryEquityOtherComprehensiveIncome

0

usd

us-gaap

Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest

NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest

2242000000

usd

us-gaap

Temporary Equity Net Income

TemporaryEquityNetIncome

0

usd

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

4.20

us-gaap

Treasury Stock Value Acquired Cost Method

TreasuryStockValueAcquiredCostMethod

1785000000

usd

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

2129000000

usd

ci

Realized Investment Gain Loss

RealizedInvestmentGainLoss

-2805000000

usd

us-gaap

Payments To Acquire Other Investments

PaymentsToAcquireOtherInvestments

1028000000

usd

us-gaap

Payments To Acquire Other Investments

PaymentsToAcquireOtherInvestments

891000000

usd

ci

Payments For Proceeds From Property Plant And Equipment

PaymentsForProceedsFromPropertyPlantAndEquipment

1069000000

usd

ci

Payments For Proceeds From Property Plant And Equipment

PaymentsForProceedsFromPropertyPlantAndEquipment

1208000000

usd

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

132000000

usd

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

443000000

usd

us-gaap

Proceeds From Divestiture Of Businesses Net Of Cash Divested

ProceedsFromDivestitureOfBusinessesNetOfCashDivested

0

usd

us-gaap

Proceeds From Divestiture Of Businesses Net Of Cash Divested

ProceedsFromDivestitureOfBusinessesNetOfCashDivested

13000000

usd

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

485000000

usd

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

117000000

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-1911000000

usd

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-4734000000

usd

us-gaap

Additions To Contract Holders Funds

AdditionsToContractHoldersFunds

120000000

usd

us-gaap

Additions To Contract Holders Funds

AdditionsToContractHoldersFunds

127000000

usd

us-gaap

Withdrawal From Contract Holders Funds

WithdrawalFromContractHoldersFunds

180000000

usd

us-gaap

Withdrawal From Contract Holders Funds

WithdrawalFromContractHoldersFunds

139000000

usd

ci

Proceeds From Repayments Of Other Short Term Debt

ProceedsFromRepaymentsOfOtherShortTermDebt

366000000

usd

ci

Proceeds From Repayments Of Other Short Term Debt

ProceedsFromRepaymentsOfOtherShortTermDebt

1484000000

usd

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

3000000000

usd

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

2967000000

usd

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

4462000000

usd

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

1491000000

usd

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

5012000000

usd

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

1740000000

usd

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

283000000

usd

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

113000000

usd

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

1183000000

usd

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

1092000000

usd

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-255000000

usd

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

-321000000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-4399000000

usd

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-3044000000

usd

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

6000000

usd

us-gaap

Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

2000000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-1153000000

usd

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

2570000000

usd

CY2023Q4

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

8337000000

usd

CY2024Q3

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

7184000000

usd

CY2023Q3

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

8546000000

usd

CY2024Q3

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations

1249000000

usd

CY2023Q3

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations

0

usd

CY2024Q3

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

5935000000

usd

CY2023Q3

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

8546000000

usd

us-gaap

Income Taxes Paid Net

IncomeTaxesPaidNet

839000000

usd

us-gaap

Income Taxes Paid Net

IncomeTaxesPaidNet

1380000000

usd

us-gaap

Interest Paid Net

InterestPaidNet

1037000000

usd

us-gaap

Interest Paid Net

InterestPaidNet

1019000000

usd

us-gaap

Nature Of Operations

NatureOfOperations

<div style="margin-bottom:10pt">Note 1 – Description of Business</div><div>The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. Powered by our people and our brands, we advance our mission to improve the health and vitality of those we serve. </div><div> </div><div>Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental and related products and services. The majority of these products and services are offered through employers and other entities such as governmental and non-governmental organizations, unions and associations. Cigna Healthcare also offers health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations.</div><div> </div><div style="margin-bottom:10pt">A full description of our segments follows:</div><div>The Evernorth Health Services reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which partner with health plans, employers, governmental organizations and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions.</div><div> </div><div>Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through Care Delivery and Management Solutions. The Company's reporting units remain aligned with its operating segments and Evernorth Health Services' goodwill was allocated on a relative fair value basis during the three months ended March 31, 2024.</div><div> </div><div style="margin-bottom:10pt">The Cigna Healthcare reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and specialty benefits and solutions for insured and self-insured clients, Medicare Advantage, Medicare Supplement and Medicare Stand-Alone Prescription Drug Plans for seniors and individual health insurance plans. International Health provides health care solutions in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. </div><div style="margin-bottom:10pt">In January 2024, the Company entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the U.S. Healthcare operating segment to Health Care Service Corporation ("HCSC") for approximately $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions, including adjustments to align with the final balance sheet of the divested businesses (the "HCSC transaction"). See Note 5 to the Consolidated Financial Statements for further information.</div><div style="margin-bottom:10pt">Other Operations comprises the remainder of our business operations, which includes our continuing business (corporate-owned life insurance ("COLI")) and our run-off and other non-strategic businesses. Our run-off businesses include (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013, (ii) settlement annuity business, and (iii) individual life insurance and annuity and retirement benefits businesses which were sold through reinsurance agreements.</div><div style="margin-bottom:10pt">Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs and eliminations for products and services sold between segments.</div>

CY2024Q3

ci

Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale

PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale

13708000000

usd

CY2023Q4

ci

Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale

PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale

8169000000

usd

CY2024Q3

ci

Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale

NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale

12615000000

usd

CY2023Q4

ci

Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale

NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale

8044000000

usd

CY2024Q3

ci

Insurance Customer Receivables Before Reclassification To Disposal Group Assets Held For Sale

InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale

2732000000

usd

CY2023Q4

ci

Insurance Customer Receivables Before Reclassification To Disposal Group Assets Held For Sale

InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale

2359000000

usd

CY2024Q3

ci

Accounts And Other Receivables Net Current Before Reclassification To Disposal Group Assets Held For Sale

AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale

323000000

usd

CY2023Q4

ci

Accounts And Other Receivables Net Current Before Reclassification To Disposal Group Assets Held For Sale

AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale

272000000

usd

CY2024Q3

ci

Receivables Net Current Before Reclassification To Disposal Group Assets Held For Sale

ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale

29378000000

usd

CY2023Q4

ci

Receivables Net Current Before Reclassification To Disposal Group Assets Held For Sale

ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale

18844000000

usd

CY2024Q3

us-gaap

Receivables Net Current

ReceivablesNetCurrent

27846000000

usd

CY2024Q3

us-gaap

Allowance For Doubtful Accounts Receivable Current

AllowanceForDoubtfulAccountsReceivableCurrent

88000000

usd

CY2023Q4

us-gaap

Allowance For Doubtful Accounts Receivable Current

AllowanceForDoubtfulAccountsReceivableCurrent

90000000

usd

CY2023Q3

ci

Accounts Receivable Uncommitted Factoring Facility Initial Term

AccountsReceivableUncommittedFactoringFacilityInitialTerm

P2Y

CY2023Q3

ci

Accounts Receivable Uncommitted Factoring Facility Automatic Renewal Term

AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm

P1Y

CY2023Q3

ci

Accounts Receivable Uncommitted Factoring Facility Total Capacity

AccountsReceivableUncommittedFactoringFacilityTotalCapacity

1000000000.0

usd

CY2024Q3

ci

Accounts Receivable Uncommitted Factoring Facility Total Capacity

AccountsReceivableUncommittedFactoringFacilityTotalCapacity

1500000000

usd

CY2024Q3

ci

Accounts Receivable Uncommitted Factoring Facility Amount Sold

AccountsReceivableUncommittedFactoringFacilityAmountSold

1300000000

usd

CY2023Q3

ci

Accounts Receivable Uncommitted Factoring Facility Amount Sold

AccountsReceivableUncommittedFactoringFacilityAmountSold

1000000000.0

usd

ci

Accounts Receivable Uncommitted Factoring Facility Amount Sold

AccountsReceivableUncommittedFactoringFacilityAmountSold

4500000000

usd

ci

Accounts Receivable Uncommitted Factoring Facility Amount Sold

AccountsReceivableUncommittedFactoringFacilityAmountSold

1000000000.0

usd

CY2024Q3

ci

Accounts Receivable Uncommitted Factoring Facility Accounts Receivable Sold That Remain Outstanding

AccountsReceivableUncommittedFactoringFacilityAccountsReceivableSoldThatRemainOutstanding

258000000

usd

CY2023Q4

ci

Accounts Receivable Uncommitted Factoring Facility Accounts Receivable Received But Not Remitted

AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted

515000000

usd

CY2023Q4

us-gaap

Supplier Finance Program Obligation Current

SupplierFinanceProgramObligationCurrent

1500000000

usd

CY2024Q3

ci

Supplier Finance Program Outstanding Payment Obligation Current Voluntarily Elected To Be Sold

SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold

534000000

usd

CY2024Q3

ci

Transaction Related Costs

TransactionRelatedCosts

77000000

usd

CY2023Q3

ci

Transaction Related Costs

TransactionRelatedCosts

13000000

usd

CY2023Q3

ci

Transaction Related Costs After Tax

TransactionRelatedCostsAfterTax

9000000

usd

ci

Transaction Related Costs

TransactionRelatedCosts

20000000

usd

ci

Transaction Related Costs After Tax

TransactionRelatedCostsAfterTax

15000000

usd

CY2023Q3

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

3073000

shares

CY2024Q3

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

278457000

shares

CY2024Q3

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

281396000

shares

CY2023Q3

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

294058000

shares

CY2023Q3

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

3073000

shares

CY2023Q3

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

297131000

shares

CY2024Q3

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

2.65

CY2024Q3

ci

Earnings Per Share Effect Of Dilution

EarningsPerShareEffectOfDilution

-0.02

CY2024Q3

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

2.63

CY2023Q3

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

4.79

CY2023Q3

ci

Earnings Per Share Effect Of Dilution

EarningsPerShareEffectOfDilution

-0.05

CY2023Q3

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

4.74

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

2010000000

usd

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

2010000000

usd

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

4135000000

usd

us-gaap

Net Income Loss Available To Common Stockholders Basic

NetIncomeLossAvailableToCommonStockholdersBasic

4135000000

usd

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

282005000

shares

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

282005000

shares

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

294752000

shares

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

294752000

shares

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

3037000

shares

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

2911000

shares

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

2911000

shares

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

282005000

shares

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

3037000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

285042000

shares

us-gaap

Weighted Average Number Of Shares Issued Basic

WeightedAverageNumberOfSharesIssuedBasic

294752000

shares

us-gaap

Incremental Common Shares Attributable To Share Based Payment Arrangements

IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

2911000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

297663000

shares

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

7.13

ci

Earnings Per Share Effect Of Dilution

EarningsPerShareEffectOfDilution

-0.08

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

7.05

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

14.03

ci

Earnings Per Share Effect Of Dilution

EarningsPerShareEffectOfDilution

-0.14

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

13.89

CY2024Q3

us-gaap

Treasury Stock Common Shares

TreasuryStockCommonShares

122500000

shares

CY2023Q4

us-gaap

Treasury Stock Common Shares

TreasuryStockCommonShares

107400000

shares

CY2023Q3

us-gaap

Treasury Stock Common Shares

TreasuryStockCommonShares

105700000

shares

CY2024Q3

us-gaap

Commercial Paper

CommercialPaper

1635000000

usd

CY2023Q4

us-gaap

Commercial Paper

CommercialPaper

1237000000

usd

CY2024Q3

ci

Other Short Term Debt Current Maturities Of Long Term Debt And Lease Obligations Current

OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent

44000000

usd

CY2023Q4

ci

Other Short Term Debt Current Maturities Of Long Term Debt And Lease Obligations Current

OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent

42000000

usd

CY2024Q3

us-gaap

Debt Current

DebtCurrent

2572000000

usd

CY2023Q4

us-gaap

Debt Current

DebtCurrent

2775000000

usd

CY2024Q3

us-gaap

Other Long Term Debt Noncurrent

OtherLongTermDebtNoncurrent

50000000

usd

CY2023Q4

us-gaap

Other Long Term Debt Noncurrent

OtherLongTermDebtNoncurrent

66000000

usd

CY2024Q3

us-gaap

Long Term Debt And Capital Lease Obligations

LongTermDebtAndCapitalLeaseObligations

30230000000

usd

CY2023Q4

us-gaap

Long Term Debt And Capital Lease Obligations

LongTermDebtAndCapitalLeaseObligations

28155000000

usd

srt

Commercial Paper Average Rate Paid

CommercialPaperAverageRatePaid

0.0533

CY2024Q1

us-gaap

Debt Instrument Repurchased Face Amount

DebtInstrumentRepurchasedFaceAmount

1800000000

usd

CY2024Q3

us-gaap

Interest Expense Debt

InterestExpenseDebt

380000000

usd

us-gaap

Interest Expense Debt

InterestExpenseDebt

1100000000

usd

CY2023Q3

us-gaap

Interest Expense Debt

InterestExpenseDebt

353000000

usd

us-gaap

Interest Expense Debt

InterestExpenseDebt

1000000000.0

usd

CY2024Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.40

CY2024Q2

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

392000000

usd

CY2024Q3

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.40

CY2024Q3

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

390000000

usd

CY2023Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.23

CY2023Q1

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

368000000

usd

CY2023Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.23

CY2023Q2

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

362000000

usd

CY2023Q3

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

1.23

CY2023Q3

us-gaap

Payments Of Dividends Common Stock

PaymentsOfDividendsCommonStock

362000000

usd

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div>The Company's insurance and contractholder liabilities were comprised of the following:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Current</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Non-current</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Current</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Non-current</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Unpaid claims and claim expenses</td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Cigna Healthcare</div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,006 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">82 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,088 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,017 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">75 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,092 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,317 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Other Operations</td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">312 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">253 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">274 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Future policy benefits</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Cigna Healthcare</div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">510 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">599 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">518 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">615 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">590 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Other Operations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">157 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,301 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,458 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,375 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,538 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,380 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom">Contractholder deposit funds</td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Cigna Healthcare</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">120 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">133 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">151 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Other Operations</td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">364 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,982 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,346 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">362 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,178 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,540 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,607 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Market risk benefits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">914 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">944 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">966 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,003 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">934 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom">Unearned premiums</td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">710 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">741 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">846 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">868 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,385 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,528 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,090 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,618 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,633 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,421 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,054 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Insurance and contractholder liabilities classified as liabilities of businesses held for sale (1)</div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,051)</td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(517)</td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,568)</td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,119)</td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(517)</td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,636)</td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Total insurance and contractholder liabilities</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,477 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,573 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">16,050 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,514 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,904 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">16,418 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">18,638 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt">(1) Amounts classified as liabilities of businesses held for sale include $937 million of Unpaid claims, $422 million of Future policy benefits, $98 million of Unearned premiums and $111 million of Contractholder deposit funds as of September 30, 2024 and $823 million of Unpaid claims, $429 million of Future policy benefits, $261 million of Unearned premiums and $123 million of Contractholder deposit funds as of December 31, 2023.</div><div style="margin-bottom:10pt">Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">2024 (1)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning balance</td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,092 </td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,176 </td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Reinsurance and other amounts recoverable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">236 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">221 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning balance, net</td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,856 </td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,955 </td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Incurred costs related to:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,314 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26,788 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Prior years</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(422)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(237)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total incurred</td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,892 </td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26,551 </td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Paid costs related to:</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Current year</td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,761 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,053 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Prior years</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,059 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,362 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total paid</td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,820 </td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,415 </td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Ending balance, net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,928 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,091 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom">Add: Reinsurance and other amounts recoverable</td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">160 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">226 </td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Ending balance</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,088 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,317 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div>(1) Includes unpaid claims amounts classified as liabilities of businesses held for sale. As of September 30, 2024 and December 31, 2023, $937 million and $823 million classified as liabilities of businesses held for sale, respectively.</div>

CY2024Q3

ci

Market Risk Benefit Liability Amount Current

MarketRiskBenefitLiabilityAmountCurrent

30000000

usd

CY2024Q3

ci

Market Risk Benefit Liability Amount Noncurrent

MarketRiskBenefitLiabilityAmountNoncurrent

914000000

usd

CY2024Q3

us-gaap

Market Risk Benefit Liability Amount

MarketRiskBenefitLiabilityAmount

944000000

usd

CY2023Q4

ci

Market Risk Benefit Liability Amount Current

MarketRiskBenefitLiabilityAmountCurrent

37000000

usd

CY2023Q4

ci

Market Risk Benefit Liability Amount Noncurrent

MarketRiskBenefitLiabilityAmountNoncurrent

966000000

usd

CY2023Q4

us-gaap

Market Risk Benefit Liability Amount

MarketRiskBenefitLiabilityAmount

1003000000

usd

CY2023Q3

us-gaap

Market Risk Benefit Liability Amount

MarketRiskBenefitLiabilityAmount

934000000

usd

CY2024Q3

ci

Unearned Premiums Current Including Disposal Groups

UnearnedPremiumsCurrentIncludingDisposalGroups

710000000

usd

CY2024Q3

ci

Unearned Premiums Noncurrent Including Disposal Groups

UnearnedPremiumsNoncurrentIncludingDisposalGroups

31000000

usd

CY2024Q3

ci

Unearned Premiums Including Disposal Groups

UnearnedPremiumsIncludingDisposalGroups

741000000

usd

CY2023Q4

ci

Unearned Premiums Current Including Disposal Groups

UnearnedPremiumsCurrentIncludingDisposalGroups

846000000

usd

CY2023Q4

ci

Unearned Premiums Noncurrent Including Disposal Groups

UnearnedPremiumsNoncurrentIncludingDisposalGroups

22000000

usd

CY2023Q4

ci

Unearned Premiums Including Disposal Groups

UnearnedPremiumsIncludingDisposalGroups

868000000

usd

CY2023Q3

us-gaap

Unearned Premiums

UnearnedPremiums

1385000000

usd

CY2024Q3

ci

Insurance And Contractholder Liabilities Current Including Disposal Groups

InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups

6528000000

usd

CY2024Q3

ci

Insurance And Contractholder Liabilities Noncurrent Including Disposal Groups

InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups

11090000000

usd

CY2024Q3

ci

Insurance And Contractholder Liabilities Including Disposal Groups

InsuranceAndContractholderLiabilitiesIncludingDisposalGroups

17618000000

usd

CY2023Q4

ci

Insurance And Contractholder Liabilities Current Including Disposal Groups

InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups

6633000000

usd

CY2023Q4

ci

Insurance And Contractholder Liabilities Noncurrent Including Disposal Groups

InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups

11421000000

usd

CY2023Q4

ci

Insurance And Contractholder Liabilities Including Disposal Groups

InsuranceAndContractholderLiabilitiesIncludingDisposalGroups

18054000000

usd

CY2024Q3

ci

Insurance And Contractholder Liabilities Current

InsuranceAndContractholderLiabilitiesCurrent

5477000000

usd

CY2024Q3

ci

Insurance And Contractholder Liabilities Noncurrent

InsuranceAndContractholderLiabilitiesNoncurrent

10573000000

usd

CY2024Q3

ci

Insurance And Contractholder Liabilities

InsuranceAndContractholderLiabilities

16050000000

usd

CY2023Q4

ci

Insurance And Contractholder Liabilities Current

InsuranceAndContractholderLiabilitiesCurrent

5514000000

usd

CY2023Q4

ci

Insurance And Contractholder Liabilities Noncurrent

InsuranceAndContractholderLiabilitiesNoncurrent

10904000000

usd

CY2023Q4

ci

Insurance And Contractholder Liabilities

InsuranceAndContractholderLiabilities

16418000000

usd

CY2023Q3

ci

Insurance And Contractholder Liabilities

InsuranceAndContractholderLiabilities

18638000000

usd

CY2024Q3

ci

Policyholder Contract Balance Percent Reinsured Externally

PolicyholderContractBalancePercentReinsuredExternally

0.38

ci

Annuitization Election Period

AnnuitizationElectionPeriod

P30D

CY2023Q4

us-gaap

Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk

MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk

1003000000

usd

CY2022Q4

us-gaap

Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk

MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk

1268000000

usd

CY2023Q4

us-gaap

Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change

MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange

1085000000

usd

CY2022Q4

us-gaap

Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change

MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange

1379000000

usd

ci

Market Risk Benefit Increase Decrease Due To Expected Run Off

MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff

-7000000

usd

ci

Market Risk Benefit Increase Decrease Due To Expected Run Off

MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff

-15000000

usd

ci

Market Risk Benefit Increase Decrease From Interest Rate Change And Equity Market Change

MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange

-78000000

usd

ci

Market Risk Benefit Increase Decrease From Interest Rate Change And Equity Market Change

MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange

-352000000

usd

us-gaap

Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected

MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected

-26000000

usd

us-gaap

Market Risk Benefit Increase Decrease From Actual Policyholder Behavior Different From Expected

MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected

-1000000

usd

us-gaap

Market Risk Benefit Increase Decrease From Other Assumption

MarketRiskBenefitIncreaseDecreaseFromOtherAssumption

37000000

usd

us-gaap

Market Risk Benefit Increase Decrease From Other Assumption

MarketRiskBenefitIncreaseDecreaseFromOtherAssumption

-16000000

usd

CY2024Q3

us-gaap

Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change

MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange

1011000000

usd

CY2023Q3

us-gaap

Market Risk Benefit Before Reinsurance And Cumulative Increase Decrease From Instrument Specific Credit Risk Change

MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange

995000000

usd

CY2024Q3

us-gaap

Aoci Market Risk Benefit Instrument Specific Credit Risk Before Tax

AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax

67000000

usd

CY2023Q3

us-gaap

Aoci Market Risk Benefit Instrument Specific Credit Risk Before Tax

AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax

61000000

usd

CY2024Q3

us-gaap

Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk

MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk

944000000

usd

CY2023Q3

us-gaap

Market Risk Benefit After Increase Decrease From Instrument Specific Credit Risk

MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk

934000000

usd

CY2024Q3

us-gaap

Market Risk Benefit Reinsurance Recoverable After Allowance

MarketRiskBenefitReinsuranceRecoverableAfterAllowance

1008000000

usd

CY2023Q3

us-gaap

Market Risk Benefit Reinsurance Recoverable After Allowance

MarketRiskBenefitReinsuranceRecoverableAfterAllowance

993000000

usd

CY2024Q3

ci

Reinsurance Recoverables Gross Before Reclassification To Disposal Group Assets Held For Sale

ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale

3961000000

usd

CY2024Q3

ci

Reinsurance Recoverable Allowance For Credit Loss Before Reclassification To Disposal Group Assets Held For Sale

ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale

30000000

usd

CY2024Q3

ci

Reinsurance Recoverables Including Reinsurance Premium Paid Before Reclassification To Disposal Group Assets Held For Sale

ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale

4939000000

usd

CY2024Q3

ci

Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale

ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale

972000000

usd

CY2024Q3

ci

Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale

LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale

16776000000

usd

CY2024Q3

ci

Investments Before Reclassification To Disposal Group Assets Held For Sale

InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale

17748000000

usd

CY2023Q4

ci

Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale

ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale

1009000000

usd

CY2023Q4

ci

Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale

LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale

19339000000

usd

CY2023Q4

ci

Investments Before Reclassification To Disposal Group Assets Held For Sale

InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale

20348000000

usd

CY2024Q3

us-gaap

Short Term Investments

ShortTermInvestments

864000000

usd

CY2024Q3

us-gaap

Long Term Investments

LongTermInvestments

15270000000

usd

CY2024Q3

us-gaap

Investments

16134000000

usd

CY2023Q4

us-gaap

Short Term Investments

ShortTermInvestments

925000000

usd

CY2023Q4

us-gaap

Long Term Investments

LongTermInvestments

17985000000

usd

CY2023Q4

us-gaap

Investments

18910000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Amortized Cost Maturity Allocated And Single Maturity Date Year One Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale

784000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year One Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale

695000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Amortized Cost Maturity Allocated And Single Maturity Date After Year One Through Five Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale

3897000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Five Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale

3806000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Amortized Cost Maturity Allocated And Single Maturity Date After Year5 Through10 Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale

3117000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year5 Through10 Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale

3033000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Amortized Cost Maturity Allocated And Single Maturity Date After Year10 Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale

2097000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year10 Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale

1994000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Maturity Without Single Maturity Date Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale

378000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Maturity Without Single Maturity Date Fair Value Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale

353000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale

10273000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Excluding Accrued Interest Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale

9881000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale

10273000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Allowance For Credit Loss Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale

104000000

usd

CY2024Q3

ci

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Before Reclassification To Disposal Group Assets Held For Sale

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale

242000000

usd

CY2024Q3

ci

Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Before Reclassification To Disposal Group Assets Held For Sale

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale

530000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Excluding Accrued Interest Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale

9881000000

usd

CY2023Q4

ci

Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale

10379000000

usd

CY2023Q4

ci

Debt Securities Available For Sale Allowance For Credit Loss Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale

33000000

usd

CY2023Q4

ci

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Before Reclassification To Disposal Group Assets Held For Sale

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale

195000000

usd

CY2023Q4

ci

Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Before Reclassification To Disposal Group Assets Held For Sale

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale

686000000

usd

CY2023Q4

ci

Debt Securities Available For Sale Excluding Accrued Interest Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale

9855000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Unrealized Loss Position Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale

5856000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Unrealized Loss Position Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale

6386000000

usd

CY2024Q3

ci

Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale

530000000

usd

CY2024Q3

ci

Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Before Reclassification To Disposal Group Assets Held For Sale

AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale

1927

position

CY2023Q4

ci

Debt Securities Available For Sale Unrealized Loss Position Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale

6633000000

usd

CY2023Q4

ci

Debt Securities Available For Sale Unrealized Loss Position Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale

7319000000

usd

CY2023Q4

ci

Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale

DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale

686000000

usd

CY2023Q4

ci

Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Before Reclassification To Disposal Group Assets Held For Sale

AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale

2353

position

CY2024Q3

us-gaap

Equity Securities Fv Ni Cost

EquitySecuritiesFvNiCost

657000000

usd

CY2024Q3

us-gaap

Equity Securities Fv Ni Current And Noncurrent

EquitySecuritiesFvNiCurrentAndNoncurrent

49000000

usd

CY2023Q4

us-gaap

Equity Securities Fv Ni Cost

EquitySecuritiesFvNiCost

656000000

usd

CY2023Q4

us-gaap

Equity Securities Fv Ni Current And Noncurrent

EquitySecuritiesFvNiCurrentAndNoncurrent

51000000

usd

CY2024Q3

ci

Equity Securities Without Readily Determinable Fair Value Amortized Cost

EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost

3117000000

usd

CY2024Q3

us-gaap

Equity Securities Without Readily Determinable Fair Value Amount

EquitySecuritiesWithoutReadilyDeterminableFairValueAmount

468000000

usd

CY2023Q4

ci

Equity Securities Without Readily Determinable Fair Value Amortized Cost

EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost

3248000000

usd

CY2023Q4

us-gaap

Equity Securities Without Readily Determinable Fair Value Amount

EquitySecuritiesWithoutReadilyDeterminableFairValueAmount

3311000000

usd

CY2024Q3

ci

Equity Securities Fvni And Without Readily Determinable Fair Value And Hybrid Instruments Amortized Cost

EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost

3774000000

usd

CY2024Q3

ci

Equity Securities Fvni And Without Readily Determinable Fair Value And Hybrid Instruments Carrying Amount

EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount

517000000

usd

CY2023Q4

ci

Equity Securities Fvni And Without Readily Determinable Fair Value And Hybrid Instruments Amortized Cost

EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost

3904000000

usd

CY2023Q4

ci

Equity Securities Fvni And Without Readily Determinable Fair Value And Hybrid Instruments Carrying Amount

EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount

3362000000

usd

CY2024Q3

ci

Other Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale

OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale

4545000000

usd

CY2023Q4

ci

Other Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale

OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale

4181000000

usd

CY2024Q3

ci

Realized Investment Gain Loss Excluding Impairments

RealizedInvestmentGainLossExcludingImpairments

25000000

usd

CY2023Q3

ci

Realized Investment Gain Loss Excluding Impairments

RealizedInvestmentGainLossExcludingImpairments

-9000000

usd

ci

Realized Investment Gain Loss Excluding Impairments

RealizedInvestmentGainLossExcludingImpairments

32000000

usd

ci

Realized Investment Gain Loss Excluding Impairments

RealizedInvestmentGainLossExcludingImpairments

-29000000

usd

CY2024Q3

ci

Debt Securities Available For Sale And Commercial Mortgage Loans Allowance For Credit Loss Expense Recovery And Impairments On Investments Total

DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal

946000000

usd

CY2023Q3

ci

Debt Securities Available For Sale And Commercial Mortgage Loans Allowance For Credit Loss Expense Recovery And Impairments On Investments Total

DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal

5000000

usd

ci

Debt Securities Available For Sale And Commercial Mortgage Loans Allowance For Credit Loss Expense Recovery And Impairments On Investments Total

DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal

2837000000

usd

ci

Debt Securities Available For Sale And Commercial Mortgage Loans Allowance For Credit Loss Expense Recovery And Impairments On Investments Total

DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal

15000000

usd

CY2024Q3

ci

Realized Investment Gain Loss

RealizedInvestmentGainLoss

-921000000

usd

CY2023Q3

ci

Realized Investment Gain Loss

RealizedInvestmentGainLoss

-14000000

usd

ci

Realized Investment Gain Loss

RealizedInvestmentGainLoss

-2805000000

usd

ci

Realized Investment Gain Loss

RealizedInvestmentGainLoss

-44000000

usd

CY2024Q3

ci

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Unrealized Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss

8000000

usd

CY2023Q3

ci

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Unrealized Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss

-4000000

usd

ci

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Unrealized Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss

3000000

usd

ci

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Unrealized Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss

-9000000

usd

CY2024Q3

ci

Guaranteed Separate Account Assets

GuaranteedSeparateAccountAssets

600000000

usd

CY2023Q4

ci

Guaranteed Separate Account Assets

GuaranteedSeparateAccountAssets

578000000

usd

CY2024Q3

ci

Non Guaranteed Separate Account Assets Classified In Fair Value Hierarchy

NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy

6400000000

usd

CY2023Q4

ci

Non Guaranteed Separate Account Assets Classified In Fair Value Hierarchy

NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy

6172000000

usd

CY2024Q3

ci

Separate Account Assets Classified In Fair Value Hierarchy

SeparateAccountAssetsClassifiedInFairValueHierarchy

7000000000

usd

CY2023Q4

ci

Separate Account Assets Classified In Fair Value Hierarchy

SeparateAccountAssetsClassifiedInFairValueHierarchy

6750000000

usd

CY2024Q3

ci

Non Guaranteed Separate Account Assets Priced At Net Asset Value As A Practical Expedient

NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient

651000000

usd

CY2023Q4

ci

Non Guaranteed Separate Account Assets Priced At Net Asset Value As A Practical Expedient

NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient

680000000

usd

CY2024Q3

us-gaap

Separate Account Assets

SeparateAccountAssets

7651000000

usd

CY2023Q4

us-gaap

Separate Account Assets

SeparateAccountAssets

7430000000

usd

CY2024Q3

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.308

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.312

CY2023Q3

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.213

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.199

CY2024Q3

us-gaap

Deferred Tax Assets Investments

DeferredTaxAssetsInvestments

836000000

usd

CY2024Q3

ci

Deferred Tax Assets Valuation Allowance Investments Subject To Federal Capital Loss Utilization Rules

DeferredTaxAssetsValuationAllowanceInvestmentsSubjectToFederalCapitalLossUtilizationRules

635000000

usd

us-gaap

Guarantees Indemnifications And Warranties Policies

GuaranteesIndemnificationsAndWarrantiesPolicies

Financial Guarantees: Retiree and Life Insurance BenefitsThe Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.Certain Other GuaranteesThe Company had indemnification obligations as of September 30, 2024 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.Guaranty Fund Assessments<div style="margin-bottom:10pt">The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions.</div>

CY2024Q3

ci

Special Items Increase Decrease To Revenues

SpecialItemsIncreaseDecreaseToRevenues

-182000000

usd

CY2024Q3

ci

Special Items.Increase Decrease To Revenues After Tax

SpecialItems.IncreaseDecreaseToRevenuesAfterTax

-138000000

usd

CY2023Q3

ci

Special Items Increase Decrease To Revenues

SpecialItemsIncreaseDecreaseToRevenues

0

usd

CY2023Q3

ci

Special Items.Increase Decrease To Revenues After Tax

SpecialItems.IncreaseDecreaseToRevenuesAfterTax

0

usd

ci

Special Items Increase Decrease To Revenues

SpecialItemsIncreaseDecreaseToRevenues

-182000000

usd

ci

Special Items.Increase Decrease To Revenues After Tax

SpecialItems.IncreaseDecreaseToRevenuesAfterTax

-138000000

usd

ci

Special Items Increase Decrease To Revenues

SpecialItemsIncreaseDecreaseToRevenues

0

usd

ci

Special Items.Increase Decrease To Revenues After Tax

SpecialItems.IncreaseDecreaseToRevenuesAfterTax

0

usd

CY2024Q3

ci

Transaction Related Costs

TransactionRelatedCosts

77000000

usd

CY2024Q3

ci

Transaction Related Costs After Tax

TransactionRelatedCostsAfterTax

59000000

usd

CY2023Q3

ci

Transaction Related Costs

TransactionRelatedCosts

13000000

usd

CY2023Q3

ci

Transaction Related Costs After Tax

TransactionRelatedCostsAfterTax

9000000

usd

ci

Transaction Related Costs

TransactionRelatedCosts

177000000

usd

ci

Transaction Related Costs After Tax

TransactionRelatedCostsAfterTax

135000000

usd

ci

Transaction Related Costs

TransactionRelatedCosts

20000000

usd

ci

Transaction Related Costs After Tax

TransactionRelatedCostsAfterTax

15000000

usd

CY2024Q3

ci

Special Item Gain Loss On Sale Of Business Before Taxes

SpecialItemGainLossOnSaleOfBusinessBeforeTaxes

-87000000

usd

CY2024Q3

ci

Special Item Gain Loss On Sale Of Business Net Of Tax

SpecialItemGainLossOnSaleOfBusinessNetOfTax

-62000000

usd

CY2023Q3

ci

Special Item Gain Loss On Sale Of Business Before Taxes

SpecialItemGainLossOnSaleOfBusinessBeforeTaxes

-21000000

usd

CY2023Q3

ci

Special Item Gain Loss On Sale Of Business Net Of Tax

SpecialItemGainLossOnSaleOfBusinessNetOfTax

-19000000

usd

ci

Special Item Gain Loss On Sale Of Business Before Taxes

SpecialItemGainLossOnSaleOfBusinessBeforeTaxes

-106000000

usd

ci

Special Item Gain Loss On Sale Of Business Net Of Tax

SpecialItemGainLossOnSaleOfBusinessNetOfTax

-19000000

usd

ci

Special Item Gain Loss On Sale Of Business Before Taxes

SpecialItemGainLossOnSaleOfBusinessBeforeTaxes

-21000000

usd

ci

Special Item Gain Loss On Sale Of Business Net Of Tax

SpecialItemGainLossOnSaleOfBusinessNetOfTax

-19000000

usd

CY2024Q3

ci

Special Item Charge Benefit Tax Matters

SpecialItemChargeBenefitTaxMatters

0

usd

CY2024Q3

ci

Special Item Charge Benefit Tax Matters After Tax

SpecialItemChargeBenefitTaxMattersAfterTax

41000000

usd

CY2023Q3

ci

Special Item Charge Benefit Tax Matters

SpecialItemChargeBenefitTaxMatters

0

usd

CY2023Q3

ci

Special Item Charge Benefit Tax Matters After Tax

SpecialItemChargeBenefitTaxMattersAfterTax

0

usd

ci

Special Item Charge Benefit Tax Matters

SpecialItemChargeBenefitTaxMatters

0

usd

ci

Special Item Charge Benefit Tax Matters After Tax

SpecialItemChargeBenefitTaxMattersAfterTax

75000000

usd

ci

Special Item Charge Benefit Tax Matters

SpecialItemChargeBenefitTaxMatters

0

usd

ci

Special Item Charge Benefit Tax Matters After Tax

SpecialItemChargeBenefitTaxMattersAfterTax

0

usd

CY2024Q3

ci

Special Item Charge Benefit Before Tax Litigation

SpecialItemChargeBenefitBeforeTaxLitigation

0

usd

CY2024Q3

ci

Special Item Charge Benefit After Tax Litigation

SpecialItemChargeBenefitAfterTaxLitigation

0

usd

CY2023Q3

ci

Special Item Charge Benefit Before Tax Litigation

SpecialItemChargeBenefitBeforeTaxLitigation

201000000

usd

CY2023Q3

ci

Special Item Charge Benefit After Tax Litigation

SpecialItemChargeBenefitAfterTaxLitigation

171000000

usd

ci

Special Item Charge Benefit Before Tax Litigation

SpecialItemChargeBenefitBeforeTaxLitigation

0

usd

ci

Special Item Charge Benefit After Tax Litigation

SpecialItemChargeBenefitAfterTaxLitigation

0

usd

ci

Special Item Charge Benefit Before Tax Litigation

SpecialItemChargeBenefitBeforeTaxLitigation

201000000

usd

ci

Special Item Charge Benefit After Tax Litigation

SpecialItemChargeBenefitAfterTaxLitigation

171000000

usd

CY2024Q3

ci

Special Item Gain Or Loss Before Tax Attributable To Reporting Entity

SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity

-346000000

usd

CY2024Q3

ci

Special Item Gain Or Loss Net Of Tax Attributable To Reporting Entity

SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity

-300000000

usd

CY2023Q3

ci

Special Item Gain Or Loss Before Tax Attributable To Reporting Entity

SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity

-235000000

usd

CY2023Q3

ci

Special Item Gain Or Loss Net Of Tax Attributable To Reporting Entity

SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity

-199000000

usd

ci

Special Item Gain Or Loss Before Tax Attributable To Reporting Entity

SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity

-465000000

usd

ci

Special Item Gain Or Loss Net Of Tax Attributable To Reporting Entity

SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity

-367000000

usd

ci

Special Item Gain Or Loss Before Tax Attributable To Reporting Entity

SpecialItemGainOrLossBeforeTaxAttributableToReportingEntity

-242000000

usd

ci

Special Item Gain Or Loss Net Of Tax Attributable To Reporting Entity

SpecialItemGainOrLossNetOfTaxAttributableToReportingEntity

-205000000

usd

CY2024Q3

ci

Non Investment Revenue

NonInvestmentRevenue

63609000000

usd

CY2024Q3

us-gaap

Net Investment Income

NetInvestmentIncome

85000000

usd

CY2024Q3

us-gaap

Revenues

63694000000

usd

CY2024Q3

ci

Realized Investment Gains Losses Equity Method Investments

RealizedInvestmentGainsLossesEquityMethodInvestments

177000000

usd

CY2024Q3

ci

Special Items Increase Decrease To Revenues

SpecialItemsIncreaseDecreaseToRevenues

-182000000

usd

CY2024Q3

ci

Segment Revenues

SegmentRevenues

63699000000

usd

CY2024Q3

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1192000000

usd

CY2024Q3

ci

Income Loss Attributable To Noncontrolling Interest Before Tax

IncomeLossAttributableToNoncontrollingInterestBeforeTax

99000000

usd

CY2024Q3

ci

Realized Investment Gain Loss Including Equity Method Subsidiaries

RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries

-744000000

usd

CY2024Q3

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

436000000

usd

CY2024Q3

ci

Special Items Increase Decrease To Revenues

SpecialItemsIncreaseDecreaseToRevenues

-182000000

usd

CY2024Q3

ci

Transaction Related Costs

TransactionRelatedCosts

77000000

usd

CY2024Q3

ci

Special Item Gain Loss On Sale Of Business Before Taxes

SpecialItemGainLossOnSaleOfBusinessBeforeTaxes

-87000000

usd

CY2024Q3

ci

Adjusted Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2619000000

usd

CY2023Q3

ci

Non Investment Revenue

NonInvestmentRevenue

48727000000

usd

CY2023Q3

us-gaap

Net Investment Income

NetInvestmentIncome

321000000

usd

CY2023Q3

us-gaap

Revenues

49048000000

usd

CY2023Q3

ci

Realized Investment Gains Losses Equity Method Investments

RealizedInvestmentGainsLossesEquityMethodInvestments

-30000000

usd

CY2023Q3

ci

Segment Revenues

SegmentRevenues

49078000000

usd

CY2023Q3

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1840000000

usd

CY2023Q3

ci

Income Loss Attributable To Noncontrolling Interest Before Tax

IncomeLossAttributableToNoncontrollingInterestBeforeTax

44000000

usd

CY2023Q3

ci

Realized Investment Gain Loss Including Equity Method Subsidiaries

RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries

-44000000

usd

CY2023Q3

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

454000000

usd

CY2023Q3

ci

Transaction Related Costs

TransactionRelatedCosts

13000000

usd

CY2023Q3

ci

Special Item Gain Loss On Sale Of Business Before Taxes

SpecialItemGainLossOnSaleOfBusinessBeforeTaxes

-21000000

usd

CY2023Q3

ci

Special Item Charge Benefit Before Tax Litigation

SpecialItemChargeBenefitBeforeTaxLitigation

201000000

usd

CY2023Q3

ci

Adjusted Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

2529000000

usd

ci

Non Investment Revenue

NonInvestmentRevenue

180776000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

696000000

usd

us-gaap

Revenues

181472000000

usd

ci

Realized Investment Gains Losses Equity Method Investments

RealizedInvestmentGainsLossesEquityMethodInvestments

238000000

usd

ci

Special Items Increase Decrease To Revenues

SpecialItemsIncreaseDecreaseToRevenues

-182000000

usd

ci

Segment Revenues

SegmentRevenues

181416000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

3260000000

usd

ci

Income Loss Attributable To Noncontrolling Interest Before Tax

IncomeLossAttributableToNoncontrollingInterestBeforeTax

271000000

usd

ci

Realized Investment Gain Loss Including Equity Method Subsidiaries

RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries

-2567000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

1279000000

usd

ci

Special Items Increase Decrease To Revenues

SpecialItemsIncreaseDecreaseToRevenues

-182000000

usd

ci

Transaction Related Costs

TransactionRelatedCosts

177000000

usd

ci

Special Item Gain Loss On Sale Of Business Before Taxes

SpecialItemGainLossOnSaleOfBusinessBeforeTaxes

-106000000

usd

ci

Adjusted Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

7300000000

usd

ci

Non Investment Revenue

NonInvestmentRevenue

143275000000

usd

us-gaap

Net Investment Income

NetInvestmentIncome

876000000

usd

us-gaap

Revenues

144151000000

usd

ci

Realized Investment Gains Losses Equity Method Investments

RealizedInvestmentGainsLossesEquityMethodInvestments

-22000000

usd

ci

Segment Revenues

SegmentRevenues

144173000000

usd

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5325000000

usd

ci

Income Loss Attributable To Noncontrolling Interest Before Tax

IncomeLossAttributableToNoncontrollingInterestBeforeTax

142000000

usd

ci

Realized Investment Gain Loss Including Equity Method Subsidiaries

RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries

-66000000

usd

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

1368000000

usd

ci

Transaction Related Costs

TransactionRelatedCosts

20000000

usd

ci

Special Item Gain Loss On Sale Of Business Before Taxes

SpecialItemGainLossOnSaleOfBusinessBeforeTaxes

-21000000

usd

ci

Special Item Charge Benefit Before Tax Litigation

SpecialItemChargeBenefitBeforeTaxLitigation

201000000

usd

ci

Adjusted Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

6859000000

usd

CY2024Q3

us-gaap

Premiums Earned Net

PremiumsEarnedNet

11436000000

usd

CY2023Q3

us-gaap

Premiums Earned Net

PremiumsEarnedNet

10998000000

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

34493000000

usd

us-gaap

Premiums Earned Net

PremiumsEarnedNet

33062000000

usd

CY2024Q3

ci

Non Investment Revenue

NonInvestmentRevenue

63609000000

usd

CY2023Q3

ci

Non Investment Revenue

NonInvestmentRevenue

48727000000

usd

ci

Non Investment Revenue

NonInvestmentRevenue

180776000000

usd

ci

Non Investment Revenue

NonInvestmentRevenue

143275000000

usd

CY2024Q3

ecd

Rule10b51 Arr Trmntd Flag

Rule10b51ArrTrmntdFlag

false

CY2024Q3

ecd

Non Rule10b51 Arr Adopted Flag

NonRule10b51ArrAdoptedFlag

false

CY2024Q3

ecd

Non Rule10b51 Arr Trmntd Flag

NonRule10b51ArrTrmntdFlag

false

Name	View Source	Status
0001739940-24-000033-index-headers.html	Edgar Link	pending
0001739940-24-000033-index.html	Edgar Link	pending
0001739940-24-000033.txt	Edgar Link	pending
0001739940-24-000033-xbrl.zip	Edgar Link	pending
ci-20240930.htm	Edgar Link	pending
ci-20240930.xsd	Edgar Link	pending
ci-20240930_g1.jpg	Edgar Link	pending
exh_311x24q3.htm	Edgar Link	pending
exh_312x24q3.htm	Edgar Link	pending
exh_321x24q3.htm	Edgar Link	pending
exh_322x24q3.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
ci-20240930_def.xml	Edgar Link	unprocessable
ci-20240930_cal.xml	Edgar Link	unprocessable
ci-20240930_lab.xml	Edgar Link	unprocessable
ci-20240930_pre.xml	Edgar Link	unprocessable
ci-20240930_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CI
Cigna Group Stock $ci

2024 Q4 Form 10-Q Financial Statement

#000173994024000033 Filed on October 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CI Cigna Group Stock $ci

2024 Q4 Form 10-Q Financial Statement

#000173994024000033 Filed on October 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CI
Cigna Group Stock $ci